✦ LIBER ✦

Biodistribution and kinetics of131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma

✍ Scribed by Schmidt, Burkhard; Reidel, Günther; Peschel, Christian; Schwaiger, Markus; Scheidhauer, Klemens; Wolf, Ingo; Baumgartl, Hans-Joachim; von Schilling, Christoph

Book ID: 113025994
Publisher: Springer
Year: 2002
Tongue: English
Weight: 63 KB
Volume: 29
Category: Article
ISSN: 0340-6997
DOI: 10.1007/s00259-002-0820-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

IDEC-C2B8 anti-CD20 (Rituximab) immunoth

IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients

✍ D.T. Nguyen; J. A. Amess; H. Doughty; L. Hendry; L.W. Diamond 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 766 KB

IDEC-C2B8 (Rituximab) anti-CD20 antibody

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

✍ M. Feuring-Buske; M. Kneba; M. Unterhalt; A. Engert; M. Gramatzki; E. Hiller; L. 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 90 KB

Cellular and molecular signal transducti

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

✍ Jazirehi, Ali R; Bonavida, Benjamin 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 329 KB

Retraction: Behr TM, Griesinger F, Rigge

Retraction: Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer. (2002) 94(4 Suppl):1363–72.

📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB